rhThrombin (recombinant human thrombin) is being developed by ZymoGenetics, Inc. as a general aid to achieving hemostasis during surgery. ZymoGenetics is developing rhThrombin, a recombinant form of human thrombin that... Thrombin is used in more than 1 million surgeries each year in the United States.
- Mechanism
- Curator reviewed
The potent hemostatic properties of thrombin derive from its ability to activate platelets directly to aggregate and adhere to damaged vessels and to catalyze the formation simultaneously of a fibrin matrix. Application of exogenous thrombin bypasses the physiological process of generating a thrombin burst by directly initiating the terminal reactions of blood clot formation. rhThrombin rapidly binds to endogenous inhibitors following either i.v. or s.c. administration.
- Primary indication
- Investigated for use/treatment in blood (blood forming organ disorders, unspecified) and hemorrhage.Curator reviewed
- Also known as
- Recombinant thrombin · Recothrom · rThrombin
Resolves to
What you can answer from here — as of March 06, 2025
Which companies are running trials of rhThrombin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account